The Modular API: Flexing Manufacturing Agility for Next-Gen Therapeutics

Modular API manufacturing has moved from a niche concept to a strategic imperative for companies developing next-generation therapeutics. The promise is seductive: shorter timelines, lower capital expenditure, and the ability to pivot between products without rebuilding a facility. But the reality is more nuanced. This guide is for process development scientists, engineering project managers, and CMC leads who are evaluating whether modular fits their pipeline—and how to execute it without costly missteps.

We assume you already understand conventional batch API manufacturing. The question here is not whether modular can work, but how to make it work for your specific molecules, regulatory context, and business constraints. We avoid hypothetical promises and instead focus on concrete trade-offs, workflow steps, and failure modes that teams encounter in practice.

Who Needs Modular API and What Goes Wrong Without It

Modular API manufacturing is not for everyone. It shines brightest for companies dealing with high-potency compounds, short product lifecycles, or multiproduct portfolios where dedicated facilities are economically unviable. Think of antibody-drug conjugate (ADC) payloads, oligonucleotide therapeutics, or on-demand production of personalized cancer vaccines. These molecules often require rapid scale-up from clinical to commercial, with frequent process changes as the candidate evolves.

Without modular agility, teams face a cascade of problems. First, the capital commitment for a traditional fixed plant is enormous—often $100 million or more—and takes 3–5 years to build and validate. For a single product with uncertain market demand, that risk can sink a small biotech. Second, changeover times between campaigns in a conventional multiproduct facility can stretch weeks, with extensive cleaning validation and documentation. For products with short shelf lives or seasonal demand, that lost time translates directly into lost revenue. Third, regulatory expectations around quality-by-design (QbD) and process understanding demand flexibility; a rigid facility makes it hard to implement process improvements post-approval.

One composite scenario illustrates the pain: a mid-size company developing a new class of RNA-based therapeutics. They built a dedicated stainless steel facility for their lead candidate. When that candidate failed in Phase II, the facility sat idle for 18 months while they tried to repurpose it for a different modality. The cleaning validation alone took nine months. Meanwhile, a competitor using modular skids had redeployed their equipment to a backup candidate within six weeks. The difference was not just speed—it was survival.

Another common failure mode is underestimating the complexity of process transfer to a modular platform. Teams often assume that because the equipment is standardized, the process will transfer seamlessly. In reality, differences in hold volumes, heat transfer coefficients, and control logic can shift impurity profiles or reaction kinetics. Without a systematic approach to characterization, a modular campaign can produce material that meets release specs but fails in downstream formulation. The cost of that discovery late in development is enormous.

So who should consider modular? Any organization that expects to manufacture multiple products over the facility's lifetime, especially if those products are early-stage or have volatile demand. Contract development and manufacturing organizations (CDMOs) are natural adopters, but even innovator companies with a single blockbuster can benefit if they anticipate line extensions or combination products. The key is to match the degree of modularity to the portfolio risk: a fully modular, skid-based facility for high-mix, low-volume; a hybrid approach for a core product with one or two backups.

Prerequisites: Context Readers Should Settle First

Before designing a modular plant or procuring skids, teams must address several foundational prerequisites. Skipping these steps is the most common reason modular projects fail to deliver their promised benefits.

Process Understanding and Design Space

Modular equipment imposes constraints on operating windows—flow rates, residence times, temperature gradients—that differ from traditional batch reactors. You need a well-characterized design space for your API process before you can map it onto modular hardware. This means investing in process development studies that identify critical process parameters (CPPs) and their acceptable ranges. If your process is still poorly understood, modular will amplify variability, not reduce it.

We recommend completing at least a risk assessment (ICH Q9) and a preliminary design-of-experiments (DoE) study on the key reaction and purification steps. The output should be a process flow diagram with known sensitivity to scale-up parameters. Without this, you are guessing which skid configuration will work.

Regulatory Strategy Alignment

Modular facilities often challenge traditional regulatory paradigms. The FDA and EMA have published guidance on continuous manufacturing and modular design, but the interpretation varies by region and product type. Early engagement with regulators is essential, especially if you plan to use the same modular line for multiple products or to make post-approval changes to the equipment configuration. A common mistake is assuming that a modular platform is inherently easier to validate; in practice, the validation burden shifts from one large system to many smaller ones, each requiring its own installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ).

We advise assembling a regulatory affairs team that has experience with modular submissions. They can help design a validation master plan that accounts for reconfiguration scenarios. For example, if you swap a filtration skid for a different model, what revalidation is triggered? Having that framework in place before procurement saves months of delay later.

Supply Chain and Vendor Qualification

Modular systems rely on a network of suppliers for skids, sensors, control systems, and single-use components. A single-source failure can halt production. Teams often overlook the qualification of these vendors under GMP requirements. A skid vendor may have excellent mechanical engineering but no experience with pharmaceutical validation. Auditing vendors early and including qualification milestones in contracts is critical.

Another supply chain reality: lead times for custom skids can exceed 12 months. If your clinical timeline is aggressive, you may need to order long-lead items before the process is fully frozen. That requires a risk-based approach—ordering generic components early and finalizing specifics later. We have seen projects where a six-month delay in skid delivery forced the team to use a backup batch facility, erasing the modular cost advantage.

Internal Team Capability

Modular manufacturing demands skills that differ from traditional operations. Process engineers need to understand continuous processing, automation logic, and PAT (process analytical technology) integration. Maintenance teams must be comfortable with modular skids that can be swapped out rather than repaired in place. Training plans should be developed early, not as an afterthought during commissioning. A common pitfall is assuming that experienced batch operators can run a modular line with minimal retraining; the cognitive shift from batch to continuous or semi-continuous operation is significant and requires deliberate upskilling.

Core Workflow: Sequential Steps in Prose

Adopting modular API manufacturing follows a structured workflow. While every project has unique aspects, the sequence below captures the essential phases that experienced teams use to maximize success.

Step 1: Process Decomposition and Modular Mapping

Start by breaking your API process into unit operations: reaction, extraction, distillation, crystallization, filtration, drying. For each unit, define the operating conditions (temperature, pressure, residence time, mixing requirements) and the material of construction needs (corrosion resistance, cleanability). Then map each unit onto a modular skid or a set of skids. Some operations may combine on one skid; others may require multiple skids in series. The goal is to create a process flow diagram where each block corresponds to a commercially available or custom-engineered module.

During this step, identify which operations are best done in continuous mode versus batch. For example, a Grignard reaction may benefit from continuous stirred-tank reactors (CSTRs) or plug-flow reactors (PFRs) for better heat management, while a crystallization might remain batch due to seed control requirements. Do not force continuous where batch is superior; modularity does not require continuous processing.

Step 2: Equipment Selection and Skid Integration

With the modular map in hand, evaluate available skid systems. Major vendors offer standardized platforms for common operations like hydrogenation, distillation, and chromatography. For specialized steps—such as high-pressure reactions or handling of potent compounds—custom skids may be needed. Create a decision matrix comparing vendor options on criteria: footprint, control system compatibility, cleaning-in-place (CIP) capability, and validation support.

Integration is often the hardest part. Skids from different vendors must communicate via a common control architecture (e.g., DeltaV or Siemens PCS 7). Define the interface requirements early: physical connections (utility lines, drains), data exchange protocols (OPC-UA, Modbus), and alarm management philosophy. We recommend building a full-scale integration test at the vendor site before shipping to your facility. This catches communication mismatches and control logic errors when they are still cheap to fix.

Step 3: Process Transfer and Scale-Down Verification

Once the skids are selected, run scale-down experiments that mimic the modular configuration. Use a pilot-scale version of the skid train to verify that the process performs as predicted. Pay special attention to residence time distribution (RTD) and heat transfer—these often deviate from batch models. If the scale-down results show a shift in yield or impurity profile, adjust the process parameters before commissioning the full-scale system.

This step is also the time to develop the control strategy. Define which parameters are controlled by feedback loops (temperature, pressure, flow) and which rely on PAT (e.g., in-line NIR for concentration). Document the control logic in a process description that will become part of the regulatory submission.

Step 4: Installation, Commissioning, and Validation

Install the skids according to the layout plan, ensuring adequate access for maintenance and cleaning. Commissioning involves checking each skid individually for proper operation, then testing the integrated train with a placebo run (using a solvent or surrogate material). The placebo run should mimic the full process sequence, including CIP and changeover procedures.

Validation follows a risk-based approach. Focus the IQ/OQ on critical instruments and control loops. For the PQ, use the actual API process (or a representative surrogate if potency is a concern) and demonstrate consistent performance across three consecutive batches. If the modular line will be used for multiple products, include a changeover validation that shows cleaning effectiveness and absence of cross-contamination.

Step 5: Ongoing Monitoring and Continuous Improvement

After validation, shift to routine manufacturing with continuous monitoring. Use the PAT data and process trends to identify drift or degradation in skid performance. Modular systems allow you to replace a single skid without requalifying the entire line—but only if you have defined the revalidation boundaries. Establish a change control procedure that triggers revalidation only for changes that affect CPPs or cleaning efficacy.

Periodically review the modular configuration against your portfolio needs. As new products enter development, assess whether they can be produced on the existing skid train or if a new module is needed. This proactive portfolio alignment is the true payoff of modular agility.

Tools, Setup, and Environment Realities

The practical implementation of modular API manufacturing depends heavily on the tools and environment you choose. Here we discuss the key categories and the trade-offs involved.

Single-Use vs. Stainless Steel

Single-use components (bags, tubing, connectors) reduce cleaning validation and changeover time, making them attractive for high-potency or multi-product facilities. However, they generate plastic waste and may leach extractables that affect sensitive APIs. Stainless steel is more durable and environmentally friendly but requires rigorous CIP validation. For next-generation therapeutics like oligonucleotides or peptides, which often involve organic solvents and extreme pH, single-use materials may not be compatible. A hybrid approach—single-use for upstream steps and stainless steel for downstream—is common.

Control Systems and PAT Integration

A modular facility's nervous system is its distributed control system (DCS). Choose a DCS that supports modular expansion and can integrate with multiple vendors' hardware. Open standards like OPC-UA facilitate this. PAT tools—such as in-line Raman, FTIR, or HPLC—should be selected based on the process analytical needs. For example, real-time reaction monitoring may require Raman, while crystallization control benefits from focused beam reflectance measurement (FBRM). The cost of PAT is not trivial; justify each sensor by the decision it enables.

Facility Design: Cleanroom Classification and Layout

Modular skids can be housed in a classified cleanroom (ISO 7 or 8) or in a controlled not-classified (CNC) environment, depending on the API's exposure risk. For potent compounds, containment isolators or RABS (restricted access barrier systems) are needed. The layout should allow for skid removal and replacement without disrupting adjacent operations. Overhead cranes or forklift access points must be planned. One often-overlooked detail is utility capacity: a modular line may have higher instantaneous demand for steam, chilled water, or compressed air than a batch line of similar throughput. Perform a utility load calculation early.

Vendor Ecosystem and Support

The market for modular API equipment includes established players like GEA, Alfa Laval, and Buchi, as well as specialized skid manufacturers. Create a shortlist of vendors who have experience in your therapeutic area. Request references from companies that have used their skids in GMP production. Be wary of vendors who promise plug-and-play integration; every modular project requires some customization. Budget for on-site vendor support during commissioning and the first production campaign.

Variations for Different Constraints

No single modular approach fits all. The optimal configuration depends on your specific constraints: product type, scale, regulatory path, and budget.

High-Potency / Cytotoxic APIs

For ADCs and other cytotoxic compounds, containment is paramount. Modular skids must be enclosed in isolators with negative pressure and HEPA filtration. Single-use systems are preferred to minimize decontamination. The trade-off is higher consumable cost and waste disposal challenges. In this scenario, the modular advantage is rapid changeover between different payloads—a critical need for CDMOs serving multiple clients.

Continuous Manufacturing for High-Volume Products

For a blockbuster oral solid dosage API, continuous manufacturing with integrated modular skids can reduce footprint and improve quality consistency. This requires a higher level of process understanding and PAT investment. The variation here is the scale: instead of multiple small skids, you may use larger continuous reactors and a single downstream train. The risk is that a single-point failure (e.g., a pump malfunction) can halt the entire line. Redundancy in critical skids is advisable.

Clinical-Scale Flexibility for Small Biotechs

Small companies with limited capital often opt for a mobile modular unit—a containerized lab that can be relocated or expanded. These units use standard skids and can be validated for GMP clinical supply. The constraint is space: you may need to run multiple campaigns in sequence rather than parallel. The variation here is the trade-off between flexibility and throughput. Some teams use a single mobile unit for both development and clinical manufacturing, which accelerates the timeline but requires careful scheduling.

Multi-Product CDMO with Diverse Modalities

A CDMO serving multiple clients across small molecules, peptides, and oligonucleotides needs a modular platform that can be reconfigured quickly. The solution is a suite of standardized skids that can be arranged in different sequences. The key constraint is cleaning validation: each product changeover must be verified. Using single-use components for wetted parts reduces this burden. The trade-off is higher operational cost per batch due to consumables, but the ability to accept a wider range of projects offsets this.

Pitfalls, Debugging, and What to Check When It Fails

Even with careful planning, modular API projects encounter problems. Below are the most common failure modes and how to diagnose them.

Inconsistent Product Quality Across Campaigns

If the API quality varies between campaigns on the same modular line, suspect a change in skid performance. Check the calibration logs for critical sensors (flow meters, temperature probes, pH meters). A drift of even 1% in flow rate can affect residence time and yield. Also verify that the cleaning procedure has not degraded seals or gaskets, causing contamination. Implement a preventive maintenance schedule based on skid usage hours, not calendar time.

Longer Changeover Times Than Expected

Changeover delays often stem from incomplete cleaning validation documentation. If the cleaning protocol requires manual verification of every surface, it will be slow. Switch to a risk-based approach: identify worst-case residues and test only those. Another cause is the lack of standardized connections; if each skid uses different fittings, disassembly and reassembly take longer. Invest in quick-connect couplings with color coding.

Control System Integration Failures

When skids from different vendors fail to communicate, the usual culprit is mismatched data types or timing. For example, one skid may send a temperature reading as a floating-point number, while the receiving system expects an integer. Create a detailed interface specification before procurement, and perform a factory acceptance test (FAT) that includes full integration. During FAT, simulate all alarm and shutdown scenarios to verify the logic.

Regulatory Rejection of Validation Package

A regulatory submission for a modular facility can be rejected if the validation strategy is not clearly linked to the process risk assessment. Reviewers want to see that each skid's critical attributes are identified and tested. A common mistake is submitting a generic validation template without tailoring it to the modular configuration. Work with a regulatory consultant who has experience with modular submissions. Also, consider submitting a pre-IND or pre-NDA meeting request to discuss the modular approach early.

Underestimating Training Needs

Operators who are used to batch processes may struggle with the continuous monitoring and control adjustments required in a modular plant. When a process deviation occurs, they may revert to batch troubleshooting habits, wasting time. Implement a training program that includes simulation-based scenarios. Use the first campaign as a supervised training period with experienced operators from the vendor. Document lessons learned and update standard operating procedures (SOPs) accordingly.

Supply Chain Disruptions for Single-Use Components

Single-use bags and tubing can have long lead times, especially if they are custom. If a critical component is backordered, production stops. Mitigate this by qualifying alternative suppliers for each component. Maintain a safety stock of high-usage items. In the design phase, prefer standard sizes that are widely available rather than custom dimensions.

When things go wrong, do not immediately blame the modular concept. Often the root cause is a failure to follow the prerequisites we outlined earlier—insufficient process understanding, inadequate vendor qualification, or incomplete training. Debug systematically: start with the process data, then move to equipment logs, then to human factors. Document each failure and the corrective action to build an institutional knowledge base that improves future campaigns.